Histogenics Corporation (NASDAQ: HSGX) and Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Histogenics Corporation has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Histogenics Corporation and Adamis Pharmaceuticals Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Histogenics Corporation 0 0 2 0 3.00
Adamis Pharmaceuticals Corporation 0 0 3 0 3.00

Histogenics Corporation currently has a consensus target price of $3.75, suggesting a potential upside of 84.73%. Adamis Pharmaceuticals Corporation has a consensus target price of $10.00, suggesting a potential upside of 146.91%. Given Adamis Pharmaceuticals Corporation’s higher probable upside, analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Histogenics Corporation.

Profitability

This table compares Histogenics Corporation and Adamis Pharmaceuticals Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Histogenics Corporation N/A -658.91% -106.38%
Adamis Pharmaceuticals Corporation -143.15% -57.74% -42.37%

Valuation & Earnings

This table compares Histogenics Corporation and Adamis Pharmaceuticals Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Histogenics Corporation N/A N/A -$16.20 million ($1.38) -1.47
Adamis Pharmaceuticals Corporation $6.47 million 20.90 -$19.43 million N/A N/A

Histogenics Corporation has higher revenue, but lower earnings than Adamis Pharmaceuticals Corporation.

Institutional and Insider Ownership

47.1% of Histogenics Corporation shares are owned by institutional investors. Comparatively, 9.9% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. 23.8% of Histogenics Corporation shares are owned by insiders. Comparatively, 9.6% of Adamis Pharmaceuticals Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Histogenics Corporation Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.